Gemcitabine sensitivity: ENT1
Spratlin, J., R. Sangha, et al. (2004). "The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma." Clin Cancer Res 10(20): 6956-6961.
Oguri, T., H. Achiwa, et al. (2007). "The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer." Cancer Lett 256(1): 112-119.
Farrell, J. J., H. Elsaleh, et al. (2009). "Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer." Gastroenterology 136(1): 187-195.
Marechal, R., J. R. Mackey, et al. (2009). "Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma." Clin Cancer Res 15(8): 2913-2919.
Matsumura, N., Y. Nakamura, et al. (2010). "The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy." BJU Int.
Santini, D., G. Schiavon, et al. (2010). "Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)." Curr Cancer Drug Targets.
Nakagawa, N., Murakami, Y., Uemura, K., Sudo, T., Hashimoto, Y., Kondo, N., and Sueda, T. (2012). "Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection." Surgery. Dec 17. .
Gemcitabine sensitivity: DCK
Ashida, R., B. Nakata, et al. (2009). "Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer." J Exp Clin Cancer Res 28: 83.
Sebastiani, V., F. Ricci, et al. (2006). "Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival." Clin Cancer Res 12(8): 2492-2497.
Fujita, H., K. Ohuchida, et al. (2010). "Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy." Neoplasia 12(10): 807-817.
Gemcitabine sensitivity: HuR
Costantino, C. L., A. K. Witkiewicz, et al. (2009). "The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase." Cancer Res 69(11): 4567-4572.
Richards, N. G., D. W. Rittenhouse, et al. (2010). "HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients." Ann Surg 252(3): 499-505; discussion 505-496.
Gemcitabine resistance: RRM1
Akita, H., Z. Zheng, et al. (2009). "Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma." Oncogene 28(32): 2903-2909.
Reynolds, C., C. Obasaju, et al. (2009). "Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer." J Clin Oncol 27(34): 5808-5815.
Nakamura, J., N. Kohya, et al. (2010). "Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma." Int J Oncol 37(4): 845-852.
Marechal, R., Bachet, J.B., Mackey, J.R., Dalban, C., Demetter, P., Graham, K., Couvelard, A., Svrcek, M., Bardier-Dupas, A., Hammel, P., et al. (2012). Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 143 664-674 e661-666.
Nakagawa, N., Murakami, Y., Uemura, K., Sudo, T., Hashimoto, Y., Kondo, N., and Sueda, T. (2012). Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Surgery. Dec 17. Online pub ahead of print.
Gong, W., J. Dong, et. al. (2012). RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: A meta-analysis. Lung Cancer. 75 :374-380.
Gemcitabine resistance: RRM2
Itoi, T., A. Sofuni, et al. (2007). "Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas." J Gastroenterol 42(5): 389-394.
Boukovinas, I., C. Papadaki, et al. (2008). "Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients." PLoS One 3(11): e3695.
Souglakos, J., I. Boukovinas, et al. (2008). "Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine." Br J Cancer 98(10): 1710-1715.